A detailed history of Sg Americas Securities, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 12,963 shares of CRNX stock, worth $694,816. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,963
Previous 79,051 83.6%
Holding current value
$694,816
Previous $3.54 Million 81.3%
% of portfolio
0.0%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

SELL
$43.83 - $54.98 $2.9 Million - $3.63 Million
-66,088 Reduced 83.6%
12,963 $662,000
Q2 2024

Jul 12, 2024

BUY
$42.12 - $51.91 $3.08 Million - $3.79 Million
73,084 Added 1224.8%
79,051 $3.54 Million
Q1 2024

May 06, 2024

BUY
$34.76 - $46.81 $207,412 - $279,315
5,967 New
5,967 $279,000
Q1 2023

Apr 28, 2023

BUY
$15.31 - $21.1 $251,068 - $346,018
16,399 Added 167.9%
26,166 $420,000
Q4 2022

Feb 02, 2023

SELL
$15.49 - $19.05 $86,108 - $105,898
-5,559 Reduced 36.27%
9,767 $179,000
Q3 2022

Oct 31, 2022

SELL
$18.11 - $22.37 $182,295 - $225,176
-10,066 Reduced 39.64%
15,326 $301,000
Q2 2022

Jul 29, 2022

BUY
$16.49 - $27.64 $418,714 - $701,834
25,392 New
25,392 $474,000
Q1 2022

Apr 29, 2022

SELL
$17.15 - $28.31 $109,176 - $180,221
-6,366 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$19.35 - $28.41 $249,634 - $366,517
-12,901 Reduced 66.96%
6,366 $181,000
Q3 2021

Nov 01, 2021

BUY
$16.88 - $25.23 $325,226 - $486,106
19,267 New
19,267 $406,000
Q3 2020

Nov 09, 2020

SELL
$13.62 - $17.66 $201,603 - $261,403
-14,802 Closed
0 $0
Q2 2020

Jul 20, 2020

BUY
$13.04 - $23.23 $193,018 - $343,850
14,802 New
14,802 $259,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.88B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.